Journal of the American Society of Hypertension
Volume 4, Issue 4 , Pages 163-173 , July 2010

Antihypertensive drug development: current challenges and future opportunities

  • Peter U. Feig, MD

      Affiliations

    • Cardiovascular Clinical Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey
    • Corresponding Author InformationCorresponding author: Peter U. Feig, MD, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., 126 E. Lincoln Ave, RY34 A200, P.O. Box 2000, Rahway, NJ 07065-0900. Tel: 732-594-3229.
    • ,
  • Sophie Roy, PhD

      Affiliations

    • Cardiovascular Basic Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey
    • ,
  • Robert J. Cody, MD

      Affiliations

    • Global Scientific Affairs, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey

Received 26 March 2010 ,Accepted 14 April 2010.

References 

  1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199–206
  2. U.S. product circular for Tekturna (aliskiren). Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021985lbl.pdf. Accessed April 26, 2010.
  3. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics. 2002;20(Suppl 3):1–10
  4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185
  5. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million?. Health Affairs. 2006;25:420–428
  6. Novello FC, Sprague JM. Benzothiadiazine dioxides as novel diuretics. J Am Chem Soc. 1957;79:2028–2029
  7. Freis ED. Treatment of essential hypertension with chlorothiazide. JAMA. 1958;166:137–141
  8. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545–556
  9. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666–676
  10. Org E, Eyheramendy S, Juhanson P, Gieger C, Lichtner P, Klopp N, et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet. 2009;18:2288–2296
  11. Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H, et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 2009;5:e100056. DOI:410.1371/journal.pgen.1000564
  12. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev. 2009;8:794–805
  13. Shen HC, Ding FX, Deng QL, Xu SY, Chen HS, Tong XC, et al. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009;19:5314–5320
  14. Shen HC, Ding FX, Wang SY, Deng QL, Zhang XP, Chen YL, et al. Discovery of a highly potent, selective and bioavailable soluble epoxide hydrolase inhibitor with excellent target engagement. J Med Chem. 2009;52:5009–5012
  15. Bleicher KH, Böhm H-J, Müller K, Alanine AI. Hit and lead generation beyond high-throughput screening. Nat Rev. 2003;2:369–378
  16. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev. 2007;6:636–649
  17. Pritchard JF, Malle J-R, Reimer MLJ, Mortimer E, Rolfe B, Mitchell NC. Making better drugs: decision gates in non-clinical drug development. Nat Rev. 2003;2:542–553
  18. Dorato MA, Engelhardt JA. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition. Regul Toxicol Pharmacol. 2005;42:265–274
  19. FDA. Guidance for industry and reviewers (draft). Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Draft guidance. Available online at: www.fda.gov/ohrms/DOCKETS/dailys/03/Apr03/040103/80064268.doc. Accessed April 26, 2010.
  20. Garthoff B, Hoffman K, Luckhaus G, Thurau K. Adequate substitution with electrolytes in toxicological testing of “loop” diuretics in dog. Tox App Pharm. 1982;165:191–202
  21. Clemo FA, Evering WE, Snyder PW, Albassam MA. Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol Pathol. 2003;31:25–31
  22. International Conference on Harmonization (ICH) - Draft Guidance. M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 11 June 2009. Available online at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm129520.htm. Accessed April 26, 2010.
  23. Myers MG, Lipicky RJ. Assessment of antihypertensive activity in regulatory setting. Blood Pressure Monit. 2001;6:309–312
  24. Temple R. How FDA currently makes decisions on clinical studies. Clin Trials. 2005;2:276–281
  25. Draft ICH consensus principle. Principles for clinical evaluation of new antihypertensive drugs. 2 March 2000. Available online at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm129461.htm. Accessed April 26, 2010.
  26. Temple R, Ellenberg SS. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455–463
  27. Ellenberg SS, Temple R. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 2: practical issues an specific cases. Ann Intern Med. 2000;133:464–470
  28. Temple RJ, Meyer R. Continued need for placebo in many cases, even when there is effective therapy. Arch Intern Med. 2003;163:371–373
  29. Al-Khatib SM, Califf RM, Hasselblad V, Alexander JH, McCrory DC, Sugarman J. Placebo-controls in short-term clinical trials of hypertension. Science. 2001;292:2013–2015
  30. DeFelice A, Willard J, Lawrence J, Hung J, Gordon MA, Karkowsky A, et al. The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis. J Hum Hypertens. 2008;22:659–668
  31. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–1034
  32. Committee for Medicinal Products for Human Use. Draft guideline on clinical investigation of medicinal products for the treatment of hypertension. January 2009. Available online at: http://www.ema.europa.eu/pdfs/human/ewp/023895endraft.pdf. Accessed April 26, 2010.
  33. Guidance to Industry. Labeling for outcome claims for drugs to treat hypertension. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER). Spring 2006. Available online at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006–4215B2–01–02-FDA-Backgrounder.pdf. Accessed April 26, 2010.
  34. Guidance for Industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. December 2008. Available online at: http://www.fda.gov/cder/guidance/8576fnl.pdf. Accessed April 26, 2010.
  35. Committee for Medicinal Products for Human Use. Concept paper for the need to update the note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders and the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension. CPMP/EWP/238/95. July 2009. Available online at: http://www.ema.europa.eu/pdfs/human/ewp/35049509en.pdf. Accessed April 26, 2010.
  36. Parati G, Omboni S, Bilo GH. Why is out-of-office blood pressure measurement needed? Home blood pressure measurements will increasingly replace ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Hypertension. 2009;54:181–187
  37. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals—part 1: blood pressure measurement in humans—a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–161
  38. Pickering TG, Shimbo D, Haas D. Current concepts: ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368–2374
  39. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55–61
  40. Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340–2346
  41. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–2415
  42. O'Rourke MF. From theory into practice: arterial hemodynamics in clinical hypertension. J Hypertens. 2002;20:1901–1915
  43. Williams B, Lacy PS, Thom SM. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the conduit artery function evaluation (CAFÉ) study. Circulation. 2006;113:1213–1225
  44. Roman MJ, Devereux RB, Kizer JR. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure. The Strong heart study. Hypertension. 2007;50:197–203
  45. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, et al. Central blood pressure measurements and antihypertensive therapy. A consensus document. Hypertension. 2007;50:154–160

PII: S1933-1711(10)00088-4

doi: 10.1016/j.jash.2010.04.003

Journal of the American Society of Hypertension
Volume 4, Issue 4 , Pages 163-173 , July 2010

Article Tools

* Image Usage & Resolution